Nivolumab 100mg Injection

$1,350

Nivolumab 100mg Injection, marketed under the brand name Opdivo, is an immunotherapy medication used to treat various types of cancer, including melanoma, non-small cell lung cancer (NSCLC), kidney cancer, and more. It functions as a checkpoint inhibitor, blocking the PD-1 receptor to enhance the body’s immune response against cancer cells.

Indications: Nivolumab 100mg Injection is approved for the treatment of several cancers, either as a monotherapy or in combination with other therapies:

  • Melanoma: Treatment of unresectable or metastatic melanoma.
  • Non-Small Cell Lung Cancer (NSCLC): Treatment of metastatic NSCLC with progression on or after platinum-based chemotherapy.
  • Renal Cell Carcinoma (RCC): Treatment of advanced RCC after prior therapy.
  • Head and Neck Cancer: Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based therapy.
  • Classical Hodgkin Lymphoma (cHL): Treatment of cHL that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin, or after three or more lines of systemic therapy that includes autologous HSCT.
  • Urothelial Carcinoma: Treatment of locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy.
  • Colorectal Cancer: Treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
  • Esophageal Squamous Cell Carcinoma (ESCC): Treatment of unresectable advanced, recurrent, or metastatic ESCC after prior chemotherapy.
  • Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma: Treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
  • Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer: Treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy.
    mechanism of action of Nivolumab 100mg injection

    mechanism of action of Nivolumab 100mg injection

  • Dosage and Administration: The recommended dosage of nivolumab varies based on the specific cancer being treated:
    • Monotherapy: 3 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks, or 240 mg every 2 weeks, or 480 mg every 4 weeks.
    • Combination Therapy: Dosing schedules may differ when nivolumab is used in combination with other therapies.
  • Treatment should be continued until disease progression or unacceptable toxicity occurs.Side Effects: Common side effects of Nivolumab 100mg Injection include:
    • Fatigue
    • Rash
    • Musculoskeletal pain
    • Pruritus (itching)
    • Diarrhea
    • Nausea
    • Cough
    • Shortness of breath
    • Decreased appetite
    • Back pain
    • Joint pain
    • Upper respiratory tract infection
    • Fever
    • Headache
    • Abdominal pain
    • Vomiting

    Serious side effects can occur, including immune-mediated adverse reactions affecting various organs. Patients should be monitored for signs and symptoms of these reactions.

Availability: Nivolumab is available in various dosages, including 100 mg/10 mL (10 mg/mL) for intravenous infusion. It is supplied in single-dose vials; any unused portion should be discarded

Important Considerations:

  • Nivolumab is administered intravenously and should be given under the supervision of a healthcare professional experienced in the use of cancer therapies.
  • Patients should be evaluated for immune-mediated adverse reactions and managed accordingly.
  • Use during pregnancy may harm the baby; women should be advised of potential risks.

For more detailed information, including comprehensive prescribing information, please refer to the official prescribing information provided by the manufacturer.

 

Website: Jyotilifecar

You may also like…

  • Sale
    Adding to cart

    Ivermectin 12mg Tablets

    Original price was: $130.Current price is: $75.
  • Adding to cart